RenovaroRENB
RENB
About: Renovaro Inc is a biopharmaceutical company. It is engaged in developing new immunotherapies to combat cancer and developing a predicative artificial intelligence-based diagnostic methodology for the use of earlier cancer detection.
Employees: 25
0
Funds holding %
of 7,296 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
323% more call options, than puts
Call options by funds: $55K | Put options by funds: $13K
117% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 6
10% more funds holding
Funds holding: 58 [Q4 2024] → 64 (+6) [Q1 2025]
0.39% less ownership
Funds ownership: 13.94% [Q4 2024] → 13.56% (-0.39%) [Q1 2025]
10% less repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 20
35% less capital invested
Capital invested by funds: $18.5M [Q4 2024] → $12M (-$6.54M) [Q1 2025]
Research analyst outlook
We haven’t received any recent analyst ratings for RENB.
Financial journalist opinion
Based on 3 articles about RENB published over the past 30 days
Neutral
GlobeNewsWire
1 week ago
Renovaro Secures Key U.S. Patent to Strengthen AI-Driven Drug Discovery and Diagnostics Platform
Expanded IP Portfolio Enhances Data Harmonization and Predictive Analytics Capabilities for High-Growth Biomedical Markets LOS ANGELES, June 03, 2025 (GLOBE NEWSWIRE) -- Renovaro Inc. (NASDAQ: RENB), a clinical-stage precision medicine company, today announced that its subsidiary BioSymetrics has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for a new patent application titled “Methods, Systems, and Frameworks for Unbiased Data in Drug Discovery Predictions” (Application No. 18/058,752).
Neutral
GlobeNewsWire
3 weeks ago
UPDATE - Renovaro Inc. Announces Expedited Trial for 2025 Lawsuit to Enforce Binding Merger Agreement with Predictive Oncology
LOS ANGELES, May 22, 2025 (GLOBE NEWSWIRE) -- Renovaro Inc. (NASDAQ: RENB), a TechBio leader focused on next-generation diagnostics, drug discovery, and genetically enhanced cancer therapies, today announced that it has received a ruling to expedite a trial in 2025 for the lawsuit it filed on May 9, 2025, in the Delaware Court of Chancery against Predictive Oncology Inc. (NASDAQ: POAI), seeking to enforce a binding merger agreement executed on January 1, 2025. According to the Verified Complaint, the companies entered into a legally binding Letter Agreement pursuant to which Predictive Oncology would merge into Renovaro in exchange for a newly created class of preferred stock.
Neutral
GlobeNewsWire
3 weeks ago
Renovaro Inc. Announces Expedited Trail for 2025 Lawsuit to Enforce Binding Merger Agreement with Predictive Oncology
LOS ANGELES, May 22, 2025 (GLOBE NEWSWIRE) -- Renovaro Inc. (NASDAQ: RENB), a TechBio leader focused on next-generation diagnostics, drug discovery, and genetically enhanced cancer therapies, today announced that it has received a ruling to expedite a trial in 2025 for the lawsuit it filed on May 9, 2025, in the Delaware Court of Chancery against Predictive Oncology Inc. (NASDAQ: POAI), seeking to enforce a binding merger agreement executed on January 1, 2025. According to the Verified Complaint, the companies entered into a legally binding Letter Agreement pursuant to which Predictive Oncology would merge into Renovaro in exchange for a newly created class of preferred stock.
Neutral
GlobeNewsWire
1 month ago
Renovaro Launches Augusta, an AI-Powered Precision Neurology Platform
New Proprietary Target Discovery and Validation Platform Integrates Multiomics, Contingent AI, Phenoclustering, and CRISPR Screens to Accelerate Drug Discovery LOS ANGELES, May 14, 2025 (GLOBE NEWSWIRE) -- Renovaro Inc. (NASDAQ: RENB), an AI-driven precision medicine company that leverages AI/ML platforms to improve outcomes for cancer and neurologically challenged patients, today announced it has launched Augusta, a Precision Neurology Platform for patient stratification, biomarker discovery, drug discovery, and validation. Augusta is focused on neurology where diagnosis and treatment have historically lagged.
Neutral
GlobeNewsWire
1 month ago
Renovaro and Amsterdam University Medical Center Announce Exclusive Collaboration to Advance Blood Platelet RNA Diagnostics
LOS ANGELES, May 13, 2025 (GLOBE NEWSWIRE) -- Renovaro Inc. (NASDAQ: RENB), a TechBio leader focused on next-generation diagnostics, drug discovery, and genetically enhanced cancer therapies, today agreed on terms for an exclusive collaboration agreement with Amsterdam University Medical Center (“Amsterdam UMC”) to jointly evaluate and develop blood platelet RNA diagnostics. This partnership marks an important step forward in the clinical validation and advancement of a promising new approach to disease detection and monitoring.
Neutral
GlobeNewsWire
1 month ago
Renovaro Secures High-Powered Computing from Nebul Through a Partnership to Accelerate Next-Generation Biomarker Discovery and Diagnostic Programs
LOS ANGELES, April 22, 2025 (GLOBE NEWSWIRE) -- Renovaro Inc. (NASDAQ: RENB), an AI-driven precision Medicine Company that leverages AI platforms to improve outcomes for cancer and neurologically challenged patients, today announced is expanding our ongoing strategic collaboration with Nebul (www.nebul.com), a leading AI cloud infrastructure company, to advance the early detection of cancer and other diseases. The partnership aims to leverage Renovaro's deep learning and ML programs with Nebul's high-performance computing (“HPC”) built on the latest platform to accelerate biomarker discovery and next-generation diagnostics.
Neutral
GlobeNewsWire
2 months ago
Renovaro and BioSymetrics Close Merger to Accelerate AI-Driven Biomarker Discovery and Precision Medicine
Strategic Combination Intended to Drive Advanced AI-Driven Drug Development and Expand Precision Medicine Applications Across Cancer and Neurology LOS ANGELES, April 09, 2025 (GLOBE NEWSWIRE) -- Renovaro Biosciences Inc. (NASDAQ: RENB), a TechBio leader focused on next-generation diagnostics, drug discovery, and genetically enhanced cancer therapies, today announced it closed its previously announced merger transaction with BioSymetrics, an artificial intelligence (AI)-driven drug discovery and precision neurology company on April 8, 2025. Renovaro's merger with BioSymetrics is designed to enhance Renovaro's data repository and biomarker discovery capabilities, as well as add in vivo validation and drug discovery to Renovaro's AI powered biomarker and diagnostic platform.
Neutral
GlobeNewsWire
2 months ago
Renovaro Provides Update to Definitive Agreement with Predictive Oncology
LOS ANGELES, April 04, 2025 (GLOBE NEWSWIRE) -- Renovaro Biosciences Inc. (NASDAQ: RENB), a TechBio leader focused on next-generation diagnostics, drug discovery, and genetically enhanced cancer therapies, today provided an update regarding its Definitive Agreement with Predictive Oncology Predictive Oncology, Inc. (NASDAQ: POAI) to initiate the previously announced integration of AI/ML platform technologies, core laboratory capabilities and business development efforts in Europe and the United States. Renovaro entered into a binding agreement merger agreement with Predictive Oncology, Inc. (“POI”) dated January 1, 2025, and supplemented with the Extension Agreement dated February 28, 2025 (collectively, the “Binding Agreements”).
Neutral
GlobeNewsWire
3 months ago
Renovaro Completes First Milestone Payment to Finalize Definitive Agreement with Predictive Oncology
Company Commits the First Tranche of Financing to Initiate the Integration of AI/ML Platform Technologies, Core Laboratory Capabilities and Business Development Efforts in Europe and the United States Renovaro's Strategic Acquisition of BioSymetrics Vastly Expands Biomarker and Drug Discovery Opportunities and the Development of Diagnostic Applications in Oncology LOS ANGELES, March 03, 2025 (GLOBE NEWSWIRE) -- Renovaro Biosciences Inc. (NASDAQ: RENB), a TechBio leader focused on next-generation diagnostics, drug discovery, and genetically enhanced cancer therapies, today announced that it has advanced the first tranche of financing to Predictive Oncology, Inc. (NASDAQ: POAI) to initiate the previously announced integration of AI/ML platform technologies, core laboratory capabilities and business development efforts in Europe and the United States. By adding Predictive's AI-driven drug discovery platform, vast biobank of more than 150,000 patient tumor samples, 200,000 pathology slides and decades of longitudinal drug response data to Renovaro's multi-disciplinary artificial intelligence, multi-omic and multi-modal data expertise, the combined company will be positioned to commercialize its drug discovery and diagnostic platforms.
Neutral
GlobeNewsWire
3 months ago
Renovaro and BioSymetrics Announce Definitive Merger Agreement to Advance AI-Driven Biomarker Discovery and Precision Medicine
Strategic Combination Aims to Accelerate Biomarker Identification, Enhance Drug Discovery, and Expand Precision Medicine Applications in Cancer and Beyond LOS ANGELES, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Renovaro Biosciences Inc. (NASDAQ: RENB), a TechBio leader focused on next-generation diagnostics, drug discovery, and genetically enhanced cancer therapies, today announced a definitive agreement to merge with BioSymetrics, an artificial intelligence (AI)-driven drug discovery and biomarker identification company. This transformative partnership is designed to enhance Renovaro's data repository, biomarker discovery capabilities, accelerate translational research, and bring precision medicine solutions to cancer and other critical disease areas.
Charts implemented using Lightweight Charts™